Bioprosthetic heart valves made from glutaraldehyde (GA)-fixed porcine aortic valves or bovine pericardium (BP) are having some advantages over mechanical valves. However, their durability is low due to the calcification and immunological rejection. Study on immunogenicity is an important part in understanding the biocompatibility of materials. Polyethylene glycol (PEG) on pericardium can control biodegradation and calcification. Also, PEG exhibits low immunogenicity. We have studied the complement activation potential and the contribution of complement factors (biologic factors) on the calcification of PEG grafted pericardium samples and compared with standard (control) glutaraldehyde-treated pericardium samples. PEG-grafted BP activated using GA and carbodiimide (EDC) could be selected for further studies since complement activation and calcification observed on these samples has been relatively low.
Get full access to this article
View all access options for this article.
References
1.
1. Ross, D.1992. "Biological valves: stented and unstented,"Cardiology and Cardiac Surgery: Current Topics, Grossi, A., Donatelli, F., Corno, A. and Brodman, R. eds., Mount Kisco, NY: Futura, pp. 203-206.
2.
2. Khor, E.1997. "Methods for the treatment of collagenous tissues for bioprostheses,"Biomaterials, 18, 95-105.
3.
3. Jayakrishnan, A. and Jameela, S. R.1996. "Glutaraldehyde as a fixative in bioprostheses and drug delivery matrices,"Biomaterials, 17, 471-484.
4.
4. Burkel, W. E., Kahn, R. H.1982. "Biocompatibility of prosthetic grafts,"Biologic and Synthetic Vascular Prosthesis, James C. Stanley ed., Grune & Stratton Inc., pp. 221-228.
5.
5. Schoen, F. J. and Levy, R. J.1984. "Bioprosthetic heart valve failure; pathology and pathogenesis,"Cardiol. Clin., 2, 717-727.
6.
6. Levy, R. J.1994. "Glutaraldehyde and calcification mechanism of bioprosthetic heart valves,"J. Heart Valve Disease, 3, 101-104.
7.
7. Moczar, M., Lecerf, L., Ginat, M. and Loisance, D.1996. "Complement activation is involved in the structural deterioration of bovine pericardial bioprosthetic heart valves,"ASAJO. J., 42, pp. M375-M381.
8.
8. Sindhu, C. V. and Chandy, T.1997. "Effect of alternative crosslinking techniques on the enzymatic degradation of bovine pericardia and their calcification,"J. Biomed. Mater. Res., 35, 357-369.
9.
9. Han, D. K., Jeong, S. V. and Kim, Y. H., 1989. "Evaluation of blood compatibility of PEG grafted and heparin immobilized polyurethanes,"J. Biomed. Mater. Res., 23, 211-228.
10.
10. Mollnes, T. E., Riesenfeld, J., Garred, R., Nordstrom, E., Hogasen, K., Fosse, E., Gotze, O. and Harboe, M., 1995. "A new model for evaluation of biocom-patibility: Combined determination of neoepitopes in blood and on artificial surfaces demonstrated reduced complement activation by immobilization of heparin,"Artif. Organs, 19, 909-917.
11.
11. Courtney, J. M., Irvine, L., Gaylor, J. D. S., and Taylor, K. M., 1992. "Blood compatibility in cardiopulmonary bypass,"Cardiovascular Biomaterials, Garth, W Hastings ed., London: Springer-Verlag, pp. 43-63.
12.
12. Carreni, M., Maillet, F., Labarre, D., Jozefowicz, M. and Kazatchkine, M. D.1988. "Specific antibodies enhance sephadex induced activation of the alternative complement pathway in human serum,"Biomaterials, 9, 514-518.
13.
13. Chandy, T., Mohanty, M., John, A., Rao, S. S. B., Sivakumar, R., Sharma, C. P. and Valiathan, M. S.1996. "Structural studies on bovine bioprosthetic tissues and their in viuo calcification: prevention via drug delivery,"Biomaterials, 17, 577-585.
14.
14. Liu, L. and Elwing, H., 1994. "Complement activation on solid surfaces as determined by C3 deposition and haemolytic consumption,"J. Biomed. Mater. Res., 28, 767-773.
15.
15. Labarre, D., Montdargent, B., Carreno, M. and Maillet, F., 1993. "Strategy for in vitro evaluation of the interactions between biomaterials and complement system,"J. Appl. Biomater., 4, 231-240.
16.
16. McConnell, I., Munro, A. and Waldmann, H., 1981. The immune system—A course on the molecular and cellular basis of immunity, Boston: BlackwellScientific Publications, pp. 40-61.
17.
17. Harris, J. R., 1990. "Erythroid Cells,"Blood Cell Biochemistry, Vol. 1, New York: Plenum, pp. 92-106.
18.
18. Walport, M., 1989. "Complement,"Immunology, Roitt, I., Brostoff, J., Male, D., ed., London: Gower, pp. 13.1-13.6.
19.
19. Levy, R. J., Schoen, F. J., Levy, J. T., Nelson, A. C., Howard, S. L. and Oshry, L. J., 1983. "Biologic determinants of dystrophic calcification and osteo-calcin deposition in glutaraldehyde preserved porcine aortic valve leaflets implanted subcutaneously in rats,"Am. J. Pathol., 113, 142-152.
20.
20. Levy, R. J., Schoen, F. J., and Golomb, G.1986. "Bioprosthetic heart valve calcification: Clinical features, pathobiology, and prospects for prevention."CRC Critical Reviews in Biocompatibility, Boca Raton, FL: CRC Press, pp 147-187.
